Malignant bowel obstruction: Tailoring treatment to individual patients

Journal of Supportive Oncology

Volumn 6, Issue 3, 2008, Pages 114-115

  Ripamonti, Carla Ida ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; OCTREOTIDE;

ABDOMINAL CANCER; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; COMORBIDITY; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HUMAN; INDIVIDUALIZATION; INTESTINE ANASTOMOSIS; INTESTINE OBSTRUCTION; INTESTINE RESECTION; MALIGNANT INTESTINE OBSTRUCTION; NOTE; NUTRITIONAL STATUS; PATIENT CARE; PROGNOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; STENT; TREATMENT PLANNING;

ABDOMINAL NEOPLASMS; ADAPTATION, PSYCHOLOGICAL; ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; INTESTINAL OBSTRUCTION; OCTREOTIDE; PATIENT CARE PLANNING; RISK ASSESSMENT;

EID: 41549087065     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage 2007;34(1 suppl):S49-S59.
2. Spiegel D. Effects of psychotherapy on cancer survival. Nat Rev Cancer 2002;2:383-389.
3. Mercadante S, Avola G, Maddaloni S, Salamone G, Aragona F, Rodolico V. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Support Care Cancer 1996;4:393-394.
4. Sartori S, Trevisani L, Nielsen I, Tassinari D, Righini E. Identification of a safe site for percutaneous endoscopic gastrostomy placement in patients with marked bowel distension: may octreotide have a role? Endoscopy 1994;26:710-711.